We selected TTK for additional studies for several reasons: (i) TTK knockdown inhibited NF-κB activity in our screens; (ii) TTK has not previously been shown to play a role in TNF sensitization or the NF-κB pathway; (iii) a role for TTK as a potential target in HNSCC has not previously been explored; and (iv) TTK small molecule inhibitors are available and in preclinical trials. This evidence concerns the gene NFKB1 and head and neck squamous cell carcinoma.